HAYA Therapeutics

HAYA Therapeutics

Biotechnology Research

Inspired to Transform, The Genome Informs - RNA-Guided Therapeutics to Target Disease Causing Cell-States

About us

HAYA Therapeutics is a precision medicines company developing RNA-guided programmable therapeutics targeting the regulatory genome for serious health conditions including cardiovascular disease and cancer. The company is using its innovative cell-state modifying platform to gain novel insights into the biology of long non-coding RNAs (lncRNAs), the ‘dark genomes’ information processing features and ‘source code’. HAYA’s lead therapeutic candidate is HTX-001, an antisense oligonucleotide targeting Wisper, which is a tissue and cell-specific cardiac lncRNA known to play a role in heart failure. The company is also developing a pipeline of lncRNA-targeting candidates for the cell-specific treatment of diseases in other tissues, including the lungs and the microenvironment of solid tumor cancers. Headquartered at the life sciences park Biopôle in Lausanne, Switzerland with laboratory facilities at JLABS @ San Diego, HAYA is led by a world-class team of experts in programmable and precision RNA-targeted therapeutics and is supported by a strong investor consortium. HAYA’s mission is to identify and develop breakthrough disease-modifying therapeutics with the potential for greater efficacy, safety, and accessibility than existing treatments.

Industry
Biotechnology Research
Company size
11-50 employees
Headquarters
Lausanne - Switzerland / San Diego - USA
Type
Privately Held
Founded
2019
Specialties
lncRNA, genomic medicines, and fibrosis

Locations

  • Primary

    Route De La Corniche 6

    SuperLab Suisse - Batiment Serine

    Lausanne - Switzerland / San Diego - USA, CH

    Get directions
  • 3210 Merryfield Row

    JLABS

    San Diego, California 92121, US

    Get directions

Employees at HAYA Therapeutics

Updates

Similar pages

Browse jobs

Funding

HAYA Therapeutics 10 total rounds

Last Round

Series unknown

Investors

Eli Lilly
See more info on crunchbase